Scarica l'app Stockscreener
3.00
4.53%
0.13
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Taysha Gene Therapies Inc. Stages Intraday Comeback — Trend ChangeJuly 2025 Big Picture & Long-Term Growth Portfolio Plans - thegnnews.com
BofA Securities Affirms ‘Buy’ Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects - MSN
Wells Fargo Raises Taysha Gene Therapies Target Price to $8.00 Amid 'Overweight' Rating - AInvest
Institutional Investors Are Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Biggest Bettors and Were Rewarded After Last Week's US$199m Market Cap Gain - 富途牛牛
Taysha Gene Therapies Inc. Consolidation Zone May Signal Accumulation2025 Fundamental Recap & Real-Time Volume Analysis Alerts - metal.it
Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome treatment boosts stock outlook - Investing.com Nigeria
Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome treatment boosts stock outlook By Investing.com - Investing.com South Africa
Taysha Gene Therapies price target raised to $14 from $11 at Canaccord - MSN
Chardan Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA) - The Globe and Mail
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $8 to $14 - 富途牛牛
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2025 Earnings Call Transcript - Insider Monkey
Positive Outlook for Taysha Gene Therapies: Buy Rating Reinforced by Strong Financial Position and Promising Clinical Progress - TipRanks
Canaccord Genuity raises Taysha Gene Therapies stock price target on pivotal study progress By Investing.com - Investing.com South Africa
Canaccord Genuity raises Taysha Gene Therapies stock price target on pivotal study progress - Investing.com Canada
Taysha plans pivotal TSHA-102 trial enrollment in Q4 2025, extends cash runway to 2028 - MSN
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates - MSN
Taysha Gene 2025 Q2 Earnings Significant Revenue Growth Despite Worsening Net Loss - AInvest
Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ... - Yahoo Finance
Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ... By GuruFocus - Investing.com Canada
Taysha Gene Therapies Advances Rett Syndrome Trials - TipRanks
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Chardan Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10 - 富途牛牛
Chardan Capital Keeps Buy Rating on Taysha Gene with PT Raised to $10 - AInvest
Taysha Gene Therapies shares rise 6.70% intraday after reporting Q2 2025 earnings. - AInvest
Transcript : Taysha Gene Therapies, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Taysha Gene Therapies' Q2 2025: Key Contradictions in Clinical Trial Endpoints and Regulatory Strategy - AInvest
Taysha Gene Therapies, Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Taysha Gene’s Q2 2025 revenue beats forecast By Investing.com - Investing.com UK
Earnings call transcript: Taysha Gene’s Q2 2025 revenue beats forecast - Investing.com
Taysha Gene Therapies reports Q2 EPS (9c), consensus (8c) - TipRanks
TSHATaysha Gene Therapies, Inc. Latest Stock News & Market Updates - Stock Titan
Is Taysha Gene Therapies Inc. benefiting from interest rate changesSteady Performer Watchlist - mustnews.co.kr
How does Taysha Gene Therapies Inc. perform in inflationary periodsBest Picks for Wealth Multiplication - newsyoung.net
Taysha Gene Therapies Inc. Reaches Critical Trendline SupportAlpha Focused Technical Trade Signals Gain Attention - beatles.ru
Podcast: Astellas SVP On Doubling Down On Gene Therapy Despite Industry Headwinds - insights.citeline.com
Taysha Gene TSHA Q2 2025 Earnings Preview Upside Potential on Strategic Partnerships and Innovation - AInvest
Wells Fargo Remains Bullish on Taysha Gene Therapies (TSHA) - MSN
Taysha Gene Therapies Inc. Breaks Losing Streak — Is the Trend ReversingPortfolio Diversification Stock Ideas From Experts - beatles.ru
Taysha Gene Therapies Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Earnings Preview: TSHA to Report Financial Results Pre-market on August 12 - 富途牛牛
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 - 富途牛牛
Taysha Gene Therapies to Release Second Quarter 2025 - GlobeNewswire
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know - Yahoo Finance
RSI Crosses Above 30 for Taysha Gene Therapies Inc. — Reversal in SightCommunity Shared Smart Money Signals Show Movement - beatles.ru
What are analysts’ price targets for Taysha Gene Therapies Inc. in the next 12 monthsDiscover undervalued stocks before they soar - Jammu Links News
What are Taysha Gene Therapies Inc. company’s key revenue driversBuild wealth with steady, reliable stocks - Jammu Links News
How many analysts rate Taysha Gene Therapies Inc. as a “Buy”Maximize gains with data-driven stock picks - Jammu Links News
What analysts say about Taysha Gene Therapies Inc. stockSuperior trading gains - Jammu Links News
10 Best Strong Buy Penny Stocks to Buy Now - Insider Monkey
What is Taysha Gene Therapies Inc. company’s growth strategyTriple returns potential - Jammu Links News
Is Taysha Gene Therapies Inc. stock overvalued or undervaluedUnlock real-time stock alerts for quick profits - Jammu Links News
How does Taysha Gene Therapies Inc. generate profit in a changing economyFree Trend-Following Techniques - Jammu Links News
What are the latest earnings results for Taysha Gene Therapies Inc.Maximize returns with strategic trading plans - Jammu Links News
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):